- Kitazume H, Iwama T, Kubo I, Ageishi Y, Suzuki A. Noreflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart) 1988; 116: 211-215.
- Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
- Abbo KM, Dooris M, Glazier S et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am ) Cardiol 1995; 75: 778-782.
- Kenner MD, Zajac EJ, Kondos GT et al. Ability of the noreflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one month followup. Am ) Cardiol 1995; 76: 861-867.
- lto H, Maruyama A, Iwakura K et al. Clinical implications of the 'no reflow' phenomenon. Circulation 1996; 93: 223-228.
- Baim DS, Carrozza JP. Understanding the 'no-reflow' problem. Cathet Cardiovasc Intervent 1996; 39: 7-8.
- Kaul U, Singh B, Sudan D et al. Primary stenting in acute myocardial infarction: a 30 days' follow up study. Cathet Cardiovasc Intervent 1999; 46: 4-10.
- Feld H, Lichstien E, Schachter J, Shani J. Early and late angiographie findings of the 'no-reflow' phenomenon following direct angioplasty as the primary treatment for acute myocardial infarction. Am Heart) 1992; 123: 782-784.
- Wilson RF, Laxson DD, Lesser )R, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; i (8642): 807-811.
- The EPIC investigators: use of a monoclonal antibody directed against the platelet glycoprotein lIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
- Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 45: 187-190.
International Journal of Cardiovascular Interventions
Volume 3, 2000 - Issue 1